Verge Genomics is a biotechnology company focused on accelerating neurodegenerative disease drug discovery by leveraging artificial intelligence and human genomics data.
Its core technology is a proprietary AI and machine learning platform that integrates and analyzes large-scale human genomics data to identify new drug targets and predict candidate compounds.
The company mainly focuses on neurodegenerative diseases, including Parkinson's disease, Alzheimer's disease, and amyotrophic lateral sclerosis (ALS).
According to public information, its business model has shifted toward partnerships and licensing its AI drug discovery platform.
Its ALS candidate VRG50635 had entered clinical trials, but according to a December 2025 announcement, the Phase 1b trial did not meet efficacy endpoints and was terminated.
The platform integrates and analyzes large-scale human genomics data, including patient genomes and gene expression data, to drive its AI models.
Public information shows Eli Lilly is an investor and partner.
As a biotech company, the platform is typically provided through research collaborations and licensing; specific terms should be obtained directly from the company.
Tempus AI is a precision medicine company that uses artificial intelligence and data platforms to integrate multimodal medical data, delivering data-driven solutions for clinical decision support, medical research and drug development.
Vectorize is an AI platform built for production environments that converts unstructured data into a vector search index optimized for Retrieval-Augmented Generation (RAG). It helps developers and enterprises quickly build and deploy applications powered by large language models, significantly shortening the data-to-intelligence development cycle.
